News

Trulicity, a GLP-1 receptor agonist, is a once-weekly, injectable solution and it comes in a ready-to-use pen with a pre-attached, hidden needle. In September, Trulicity received a positive

Patient enrollment in the trial is being carried out at European oncology centers such as Radboud University Medical Center in the Netherlands), the Jules Bordet Institute in Belgium

OBT357 is a defucosylated, recombinant, humanized antibody targeting an undisclosed antigen expressed on AML blasts and the AML stem cell compartment. The trial is the first of five

In NMO patients, chronic, uncontrolled complement activation results in severe damage to the central nervous system (CNS), mainly impacting the optic nerve and spinal cord. This disease is

Haemophilia A is a rare chronic bleeding disorder that leads to inadequate clotting of the blood in response to any type of injury or surgery. Patients with haemophilia

This product is the generic version of BREVIBLOC, which is indicated for supraventricular tachycardia or noncompensatory sinus tachycardia, and intraoperative and postoperative tachycardia and/or hypertension. Mylan believes that

The potential application of E-selectin in the clinic is based on the role that the compound plays in coordinating and responding to the immune system’s activation and resulting

Acne vulgaris is a common skin disorder that affects 40 to 50 million people in the United States. "We are very pleased that the FDA has approved this

Trimel expects one or more claims in such patent to be eligible for listing in the Food and Drug Administration (FDA) Orange Book in connection with NATESTO™. The